This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Prognostic impact of absolute peripheral blood NK cell count after four cycles of R-CHOP-like regimen treatment in patients with diffuse large B cell lymphoma
Clinical and Experimental Medicine Open Access 08 November 2023
-
Identification of leukocyte-lymphocyte ratio as a novel prognostic factor in Peripheral T-cell lymphoma
Holistic Integrative Oncology Open Access 26 October 2023
-
A new nomogram for assessing complete response (CR) in gastric diffuse large B-cell lymphoma (DLBCL) patients after chemotherapy
Journal of Cancer Research and Clinical Oncology Open Access 29 May 2023
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Porrata LF, Ristow KM, Markovic SN, Persky D, Habermann TM . Lymphocyte count persistence and early recovery predicts superior survival and is independent of the international prognostic index in patients treated with CHOP chemotherapy for diffuse large B cell lymphoma. Blood 2004; 104: 3252.
Porrata LF, Ristow KM, Geyer SM, Markovic SN, Persky DO, Colgan JP et al. Absolute lymphocyte count recovery predicts superior survival and is independent of the international prognostic index in patients treated with CHOP or R-CHOP chemotherapy for diffuse large B cell lymphoma. Blood 2005; 106: 931.
Siddiqui M, Ristow K, Markovic SN, Witzig TE, Habermann TM, Colgan JP et al. Absolute lymphocyte count predicts overall survival in follicular lymphomas. Br J Haematol 2006; 134: 596–601.
A predictive model for aggressive non-Hodgkin's lymphoma. The international non-Hodgkin's lymphoma prognostic factors project. N Engl J Med 1993; 329: 987–994.
Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235–242.
Manches O, Lui G, Chaperot L, Gressin R, Molens JP, Jacob MC et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin's lymphomas. Blood 2003; 101: 949–954.
Cartron G, Watier H, Golay J, Solal-Celigny P . From the bench to the bedside: ways to improve rituximab efficacy. Blood 2004; 104: 2635–2642.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu)
Supplementary information
Rights and permissions
About this article
Cite this article
Kim, D., Baek, J., Chae, Y. et al. Absolute lymphocyte counts predicts response to chemotherapy and survival in diffuse large B-cell lymphoma. Leukemia 21, 2227–2230 (2007). https://doi.org/10.1038/sj.leu.2404780
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404780
This article is cited by
-
Prognostic impact of absolute peripheral blood NK cell count after four cycles of R-CHOP-like regimen treatment in patients with diffuse large B cell lymphoma
Clinical and Experimental Medicine (2023)
-
A new nomogram for assessing complete response (CR) in gastric diffuse large B-cell lymphoma (DLBCL) patients after chemotherapy
Journal of Cancer Research and Clinical Oncology (2023)
-
The role of comorbidity indices and histochemical markers in surgically resected and non-resected primary central nervous system lymphoma
Clinical and Experimental Medicine (2023)
-
Identification of leukocyte-lymphocyte ratio as a novel prognostic factor in Peripheral T-cell lymphoma
Holistic Integrative Oncology (2023)
-
Enhancement of the International prognostic index with β2-microglobulin, platelet count and red blood cell distribution width: a new prognostic model for diffuse large B-cell lymphoma in the rituximab era
BMC Cancer (2022)